Showing 1–12 of 19 results

Show sidebar

AFANIX 40 MG

DESCRIPTION Afatinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)

AXINIX 1 MG

DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one

AXINIX 5 MG

DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one

CRIZOCENT 250 MG

Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including

CRIZONIX 250 MG

 Crizonix Capsule 250 mg Indications Crizotinib is a kinase inhibitor indicated for the treatment of patients with- Metastatic non-small cell lung

HERNIX 40 MG

 Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of

LAPANIX 250 MG

LAPANIX 250 MG Lapatinib Beacon Pharmaceuticals Ltd. Product Description: Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase

LENVANIX 10 MG

Lenvanix (lenvatinib) 10 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor

LENVANIX 4 MG

Lenvanix (lenvatinib) 4 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor

OBETIX 5 MG

DESCRIPTION Product Description: Obetix is the only choice for Primary Biliary Cirrhosis (PBC) with the combination of UDCA (Ursodeoxycholic Acid)

PALBONIX 125 MG

DESCRIPTION Product Description: Palbociclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

REGONIX 40 MG

Product Description: Regorafenib is an oral multi-kinase inhibitor involved in normal cellular functioning and in pathological processes such as oncogenesis,